Publications

2019

Mancuso CJ, Magro CM, Lipner SR. Acquired digital fibrokeratoma presenting as a painless nodule on the right fifth fingernail. Cutis. 2019;103(6):340-342.
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, et al. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clin Cancer Res. 2019;25(2):573-583.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
DeSimone RA, Hayden JA, Mazur CA, Vasovic LV, Sachais BS, Zhao Z, et al. Red blood cells donated by smokers: A pilot investigation of recipient transfusion outcomes. Transfusion. 2019;59(8):2537-2543.
Navrazhina K, Hibler BP, Magro CM, Wildman HF. Beach Bummer: A Recurrent Pruritic Buttocks Eruption Following Travel. Am J Med. 2019;132(8):931-933.
Gaffney C, Golan R, Cantu MD, Scognamiglio T, McCarthy H, Mosquera JM, et al. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. J Urol. 2019;202(1):96-101.
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, et al. TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. Lung Cancer (Auckl). 2019;10:81-86.
Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, et al. p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell. 2019;35(1):46-63.e10.
Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing . J Clin Microbiol. 2019;57(5).

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700